Navigation Links
Neuropathy in Medical Technology
... significantly reduced pain caused by diabetic neuropathy in a double-blind, placebo-controlled trial. The ... of ARC-4558 for the treatment of painful diabetic neuropathy (PDN).
According to the abstract, patients ... the study.
About Painful Diabetic neuropathy (PDN)
...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral ...
... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite ...
... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite ...
... additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown ... Phase 1 clinical studies of SB-509 in diabetic neuropathy have shown that the drug is well tolerated. Data ... and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs ...
... (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% ... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell ...
... in subjects with mild to moderate diabetic neuropathy over the six month trial period after a single ... with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509 ... scoring systems. These include the Total neuropathy Score (TNS) and the narrower ...
... and neutropenia. No grade 4 peripheral neuropathy was observed. About Multiple Myeloma Multiple ... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and ...
... reporting either severe sporadic or cumulative neuropathy was approximately 50% lower in the Tavocept arm ... discontinuance of chemotherapy treatment due to neuropathy in the Tavocept arm of the study, compared to the ... measured neuropathy only in terms of cumulative neuropathy and they were inconclusive. BioNumerik and ASKA ...
... and a trend towards improvement in Total neuropathy Score (TNS), suggesting an alteration of disease ... to moderate diabetic peripheral sensory motor neuropathy in the legs. A total of 102 subjects have been ... and feet. The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...
... activities. In this recently published study, a model of a human neuropathy was created in the fruit fly (Drosophila) by introducing mutations in the ... do not cause a loss in the protein synthesis activity, indicating that the neuropathy arises from distinct activities of this tRNA synthetase. This work ...
... of care for metastatic colorectal cancer, but is associated with severe neuropathy at increasing cumulative doses approaching 800 mg/meter squared. This ... showed evidence of severe neurotoxicity. Three different measurements of neuropathy were statistically significant for FOLPI as a potential neuropathy-sparing ...
... hematologic (p <0.001) and gastrointestinal (p = 0.004) adverse events. neuropathy occurred more frequently in the OPAXIO arm compared with the control arm (30 percent versus 5 percent, (p <0.001)), and grade 3 neuropathy occurred in 4 percent of the OPAXIO patients, with no occurrences of grade ...
... and reversible. Neutropenia was the dose-limiting toxicity (DLT). Mild neuropathy (grade 1) was observed in 3 of 33 patients (9 percent) and was unrelated to cumulative picoplatin dose. Neuropathy was infrequent, and no neuropathy of grade 2 or greater was observed. PSA response rate was 65 percent (20 ...
... is prescribed in combination with other anti-myeloma therapies. Peripheral neuropathy is a potentially severe, adverse effect of treatment with Thalidomide that ... not be used in patients with clinical signs or symptoms of peripheral neuropathy unless the clinical benefits outweigh the risks. Symptoms may occur some ...
... 1.0 to 1.3 mg/mm2. No dose- limiting toxicity and no grade 3 peripheral neuropathy were reported. Toxicities were generally well managed and ... perifosine regimen. Toxicity was manageable with no DVT or peripheral neuropathy reported. Twenty-one patients had perifosine reduced from 150 to 100 mg qd ...
... - Phase 1 CRC Data Support Picoplatin's Lack of neuropathy and Use in Combination Therapy - SOUTH SAN ... can be administered safely in this patient population. In the trial, no neuropathy greater than grade 1 has been observed in all patients treated, including ...
... peripheral neuropathy. Conditions associated with diabetic peripheral neuropathy include numbness, skin ulcers, constant pain or extreme sensitivity to ... issued on a Phase II(b) Clinical Study of QR-333 on Diabetic Peripheral neuropathy stating that over 100 subjects had been enrolled, 52 subjects had ...
... and nutrition: Common: Dehydration. Nervous system: Very common: neuropathy - sensory. Common: neuropathy - motor, dysgeusia. Renal and urinary: Very common: Creatinine elevation, ...
... Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other ...
... the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year. "Nerve growth factor has long been of interest as a potential therapy for neuropathies and neurodegenerative diseases, ...
... chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with ...
... peripheral neuropathy, a common side effect associated with the approved proteasome inhibitor, bortezomib. Exacerbation of pre-existing peripheral neuropathy was rare and did not result in dose reductions or discontinuation of therapy. Overall, adverse events did not limit treatment duration, even among ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral ...
... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite ...
... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated) (39%), thrombocytopenia and appetite ...
Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives
... trials ongoing for the treatment of diabetic neuropathy (DN) and one to evaluate its use in the treatment ... of SB-509 in subjects with diabetic neuropathy (DN) demonstrating that the drug is ... and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs ...... additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown ... Phase 1 clinical studies of SB-509 in diabetic neuropathy have shown that the drug is well tolerated. Data ... and clinical effect in patients with diabetic neuropathy and ALS. Other therapeutic development programs ...
... (49% vs 46%), nausea (48% vs 28%), peripheral neuropathy (47% vs 5%), diarrhea (46% vs 17%), anemia (43% ... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell ...
... in subjects with mild to moderate diabetic neuropathy over the six month trial period after a single ... with mild to moderate diabetic peripheral neuropathy enrolled in Sangamo's Phase 1b study of SB-509 ... scoring systems. These include the Total neuropathy Score (TNS) and the narrower ...
... and neutropenia. No grade 4 peripheral neuropathy was observed. About Multiple Myeloma Multiple ... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and ...
... reporting either severe sporadic or cumulative neuropathy was approximately 50% lower in the Tavocept arm ... discontinuance of chemotherapy treatment due to neuropathy in the Tavocept arm of the study, compared to the ... measured neuropathy only in terms of cumulative neuropathy and they were inconclusive. BioNumerik and ASKA ...
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and ...Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
... clinical development program in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics ... 1b study of SB-509 in subjects with diabetic neuropathy (DN). Data from the Phase 1b clinical trial ... in subjects with mild to moderate diabetic neuropathy over a six month period after a single ...Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
... with picoplatin exhibited a Grade 3 or higher neuropathy and only 9 of 45 patients (20 percent) experienced mild neuropathy. No neuropathy of Grade 2 or greater was observed in the 26 ... further evaluate efficacy and safety, including neuropathy of picoplatin in combination with 5-FU and LV ...Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
... mucositis/stomatitis (20% vs 5%), peripheral neuropathy (42% vs 45%), neuralgia (17% vs 20%), and rash ... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ...... and a trend towards improvement in Total neuropathy Score (TNS), suggesting an alteration of disease ... to moderate diabetic peripheral sensory motor neuropathy in the legs. A total of 102 subjects have been ... and feet. The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...
... Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. ... diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, ...
... activities. In this recently published study, a model of a human neuropathy was created in the fruit fly (Drosophila) by introducing mutations in the ... do not cause a loss in the protein synthesis activity, indicating that the neuropathy arises from distinct activities of this tRNA synthetase. This work ...
... of care for metastatic colorectal cancer, but is associated with severe neuropathy at increasing cumulative doses approaching 800 mg/meter squared. This ... showed evidence of severe neurotoxicity. Three different measurements of neuropathy were statistically significant for FOLPI as a potential neuropathy-sparing ...
... hematologic (p <0.001) and gastrointestinal (p = 0.004) adverse events. neuropathy occurred more frequently in the OPAXIO arm compared with the control arm (30 percent versus 5 percent, (p <0.001)), and grade 3 neuropathy occurred in 4 percent of the OPAXIO patients, with no occurrences of grade ...
Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
... in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN). The study is designed to evaluate the clinical safety and clinical ... of diabetic neuropathy. About Diabetic Neuropathy Diabetic peripheral neuropathy is one of the most frequent complications of diabetes. Symptoms include ...... and reversible. Neutropenia was the dose-limiting toxicity (DLT). Mild neuropathy (grade 1) was observed in 3 of 33 patients (9 percent) and was unrelated to cumulative picoplatin dose. Neuropathy was infrequent, and no neuropathy of grade 2 or greater was observed. PSA response rate was 65 percent (20 ...
... is prescribed in combination with other anti-myeloma therapies. Peripheral neuropathy is a potentially severe, adverse effect of treatment with Thalidomide that ... not be used in patients with clinical signs or symptoms of peripheral neuropathy unless the clinical benefits outweigh the risks. Symptoms may occur some ...
... 1.0 to 1.3 mg/mm2. No dose- limiting toxicity and no grade 3 peripheral neuropathy were reported. Toxicities were generally well managed and ... perifosine regimen. Toxicity was manageable with no DVT or peripheral neuropathy reported. Twenty-one patients had perifosine reduced from 150 to 100 mg qd ...
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
... with bortezomib included thrombocytopenia (Grade 3-4 at 1.3 mg/m2) and neuropathy (Grade 1-2, at 1.3 mg/m2). A lower than anticipated rate of neuropathy was observed in the tanespimycin plus bortezomib combination, and no ...... - Phase 1 CRC Data Support Picoplatin's Lack of neuropathy and Use in Combination Therapy - SOUTH SAN ... can be administered safely in this patient population. In the trial, no neuropathy greater than grade 1 has been observed in all patients treated, including ...
... peripheral neuropathy. Conditions associated with diabetic peripheral neuropathy include numbness, skin ulcers, constant pain or extreme sensitivity to ... issued on a Phase II(b) Clinical Study of QR-333 on Diabetic Peripheral neuropathy stating that over 100 subjects had been enrolled, 52 subjects had ...
... and nutrition: Common: Dehydration. Nervous system: Very common: neuropathy - sensory. Common: neuropathy - motor, dysgeusia. Renal and urinary: Very common: Creatinine elevation, ...
NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
... chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with ...Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology
... Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other ...... Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other ...
... the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year. "Nerve growth factor has long been of interest as a potential therapy for neuropathies and neurodegenerative diseases, ...
... chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with ...
... peripheral neuropathy, a common side effect associated with the approved proteasome inhibitor, bortezomib. Exacerbation of pre-existing peripheral neuropathy was rare and did not result in dose reductions or discontinuation of therapy. Overall, adverse events did not limit treatment duration, even among ...
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
... PBGD protein in an animal model of AIP. In this model, the therapy completely prevented the occurrence of attacks and significantly ameliorated the neuropathy that develops in untreated mice. AMT-021 is intended to provide long-term normalization of the PBGD protein in order to prevent acute porphyric ...Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
... radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains unclear. Exercise caution in considering the use of ...Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
... is associated with significant side effects including neuropathy, which can limit its use and result in its discontinuation. Effective first-line, neuropathy sparing treatment for CRC is a major unmet medical need. About Prostate Cancer More than 1 million American men are currently living ...Other ContentsOther Tags
(Date:5/23/2013)... tight wrapping of genomic DNA around nucleosomes in ... expression. A team of Ludwig-Maximilians-Universitaet (LMU) in Munich ... to be locally displaced from nucleosomes for transcription. ... stored in the cell nucleus, wrapped around disk-shaped ... of four different histone proteins and accommodating two ...
(Date:5/23/2013)... A new report from the Institute of Medicine says ... at least 60 minutes of vigorous or moderate intensity ... half of American youth meet current evidence-based guidelines of ... physical activity daily, according to the report, which was ... for nearly half of their waking hours, the committee ...
(Date:5/23/2013)... of the world,s largest and fastest growing open-access ... Frontiers in Bioengineering and Biotechnology . ... Frontiers in Bioengineering and Biotechnology will ... emerging bioengineering and biotechnology research to be disseminated ... and Biotechnology will provide an open-science and ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2(Date:5/25/2013)... 25, 2013 By working diligently for ... the integration of the 2012 Lamborghini Aventador into their ... latest entrant in the list of vehicles lined by ... is all set to thrill automobile lovers in the ... and spectacular looks, the 2012 Lamborghini Aventador comes with ...
(Date:5/25/2013)... Many orthodontists have thought about moving their ... cloud is. Most people would naturally assume that ... their cloud service and support would own and maintain ... selling, they'd be wrong. Cloud providers lease space ... facility that houses servers and related equipment to run ...
(Date:5/25/2013)... Acuity Games ’ innovative brain games have come ... Hunt is available today, expanding it beyond its iPad ... Sudoku and Matchematics will roll out over the next 30 ... brain fitness measurement have been re-optimized for the iPhone's 3.5 ... fitness measurement in your pocket. What could be better?” ...
(Date:5/25/2013)... Prairie Living at Chautauqua , a BMA ... Cross Blood Drive from 1:30 to 5:30 p.m. on ... at 955 Villa Ct. in Carbondale, Illinois, serves older ... need some help to maintain their independence.. , "Come ... Frey, Director of Marketing for Prairie Living. , For ...
(Date:5/25/2013)... Ayurveda is the traditional medicine of ... of life". While a medical science, its scope enters into ... Its fundamental philosophy is that disease is the end result ... that in order to re-establish optimal health, we must discover ... a life style which brings us back into harmony. , ...
Breaking Medicine News(10 mins):Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2Health News:Acuity Games Apps Come to the iPhone 2Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2[0] Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador[0] Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other[0] Acuity Games Apps Come to the iPhone[0] Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive[0] Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes
hydroxidePPDazotemiaSupranuclearElasticumcerebrivenoaspergillomaPusarteriographyMortisinfantumTaybikeratoses
Other Tags| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |